Insulet Co. (NASDAQ:PODD) Shares Purchased by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC grew its position in shares of Insulet Co. (NASDAQ:PODD) by 14.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,345 shares of the medical instruments supplier’s stock after acquiring an additional 548 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Insulet were worth $1,011,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Sumitomo Mitsui Trust Holdings Inc. increased its position in Insulet by 0.9% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 167,871 shares of the medical instruments supplier’s stock worth $28,773,000 after purchasing an additional 1,560 shares in the last quarter. First Trust Direct Indexing L.P. increased its position in shares of Insulet by 50.0% in the first quarter. First Trust Direct Indexing L.P. now owns 2,111 shares of the medical instruments supplier’s stock worth $362,000 after acquiring an additional 704 shares in the last quarter. Norden Group LLC raised its stake in shares of Insulet by 52.4% in the 1st quarter. Norden Group LLC now owns 2,718 shares of the medical instruments supplier’s stock valued at $466,000 after acquiring an additional 934 shares during the period. Janney Montgomery Scott LLC lifted its holdings in shares of Insulet by 34.4% during the 1st quarter. Janney Montgomery Scott LLC now owns 10,060 shares of the medical instruments supplier’s stock valued at $1,724,000 after acquiring an additional 2,573 shares in the last quarter. Finally, Tobam purchased a new stake in Insulet during the 1st quarter worth $54,000.

Insulet Stock Performance

Shares of PODD stock opened at $235.61 on Monday. The stock has a market capitalization of $16.52 billion, a price-to-earnings ratio of 42.84, a PEG ratio of 4.32 and a beta of 1.22. Insulet Co. has a one year low of $137.68 and a one year high of $243.98. The company’s 50-day simple moving average is $227.10 and its 200-day simple moving average is $201.40. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). The firm had revenue of $488.50 million for the quarter, compared to the consensus estimate of $488.00 million. Insulet had a return on equity of 30.73% and a net margin of 21.11%. The company’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.38 EPS. Equities analysts anticipate that Insulet Co. will post 3.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. BTIG Research raised their price objective on Insulet from $250.00 to $260.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Citigroup boosted their price target on Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. Piper Sandler upped their price target on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. Canaccord Genuity Group lifted their price objective on shares of Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Finally, UBS Group upped their target price on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $242.29.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.